1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
- 2021
-
Mark
Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis : Results From the SPARTAKUS Cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
- 2019
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
- 2017
-
Mark
Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy : A population-based regional cohort study from southern Sweden
(
- Contribution to journal › Article
- 2016
-
Mark
Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis : Observational Data from Southern Sweden
(
- Contribution to journal › Article
- 2015
-
Mark
Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients - baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
(
- Contribution to journal › Article
- 2014
-
Mark
Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort
(
- Contribution to journal › Article